We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+13.35%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.41B
AUM Growth
-$85.8M
Cap. Flow
-$78.4M
Cap. Flow %
-3.25%
Top 10 Hldgs %
66.5%
Holding
55
New
2
Increased
13
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
NAMS icon
NewAmsterdam Pharma
NAMS
+$65M
2
PLRX icon
Pliant Therapeutics
PLRX
+$15.3M
3
KALV
KalVista Pharmaceuticals
KALV
+$12.4M
4
TRVI icon
Trevi Therapeutics
TRVI
+$10.5M
5
PVLA
Palvella Therapeutics
PVLA
+$10M

Top Sells

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$49.7M
2
KRYS icon
Krystal Biotech
KRYS
+$35.5M
3
PCVX icon
Vaxcyte
PCVX
+$33.8M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$30.2M
5
TYRA icon
Tyra Biosciences
TYRA
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
51
Aclaris Therapeutics
ACRS
$793M
– –
-264,377
Closed -$304K
NUVB icon
52
Nuvation Bio
NUVB
$2.02B
– –
-1,218,236
Closed -$2.79M
PBYI icon
53
Puma Biotechnology
PBYI
$434M
– –
-3,062,558
Closed -$7.81M
PEPG icon
54
PepGen
PEPG
$156M
– –
-702,694
Closed -$6.01M
TYRA icon
55
Tyra Biosciences
TYRA
$1.91B
– –
-731,020
Closed -$17.2M
1 2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q4 2024 Portfolio in Review

As of Q4 2024, Frazier Life Sciences Management held 55 positions worth $2.41B, down 3.4% from $2.5B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Frazier Life Sciences Management withdrew a net $78.4M in Q4 2024, closing 5 positions and reducing 9 holdings. Its most notable exit was Tyra Biosciences, an estimated $17.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Frazier Life Sciences Management opened a new position in Pliant Therapeutics worth $14.8M.

  • Frazier Life Sciences Management's largest Q4 2024 buy was Pliant Therapeutics: 1,120,803 shares worth $14.8M.
  • Frazier Life Sciences Management added most to NewAmsterdam Pharma in Q4 2024, an estimated $65M increase.
  • Frazier Life Sciences Management's biggest Q4 2024 reduction was Edgewise Therapeutics, cutting an estimated $49.7M.
  • Frazier Life Sciences Management fully exited Tyra Biosciences in Q4 2024, selling an estimated $17.2M.
  • Frazier Life Sciences Management's ten largest holdings make up 67% of its $2.41B portfolio in Q4 2024.
  • Frazier Life Sciences Management opened 2 new positions and closed 5 in Q4 2024.
  • Frazier Life Sciences Management's portfolio value fell 3.4% quarter-over-quarter to $2.41B.

Based on Frazier Life Sciences Management's 13F filing for Q4 2024, filed 18 Feb 2025.